EGPA: Benralizumab (BEN) or Mepolizumab (MEP) A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that BEN was noninferior to MEP for the induction of remission of patients with relapsing or refractory EGPA. https://t.co/1F8hBCOaFV https://t.co/smTSIY1HA3